|
JPH11511326A
(ja)
*
|
1995-08-30 |
1999-10-05 |
ジエンザイム コーポレイション |
アデノウィルスおよびａａｖの精製
|
|
US20020088014A1
(en)
*
|
1996-05-31 |
2002-07-04 |
Xiangming Fang |
Minimal adenovirus mediated recombinant vaccine
|
|
JP2000514290A
(ja)
|
1996-07-01 |
2000-10-31 |
ローヌ―プーラン・ロレ・エス・アー |
組換えアデノウイルスの製造方法
|
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
|
EP0968284B1
(en)
|
1996-11-20 |
2006-12-13 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
US6544769B1
(en)
|
1996-12-13 |
2003-04-08 |
Schering Corporation |
Compostions comprising viruses and methods for concentrating virus preparations
|
|
US6261823B1
(en)
|
1996-12-13 |
2001-07-17 |
Schering Corporation |
Methods for purifying viruses
|
|
US6995006B2
(en)
*
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
DE69836092T2
(de)
*
|
1997-10-24 |
2007-05-10 |
Invitrogen Corp., Carlsbad |
Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
|
|
US7705602B2
(en)
*
|
1997-11-03 |
2010-04-27 |
Midtronics, Inc. |
Automotive vehicle electrical system diagnostic device
|
|
US20040204381A1
(en)
*
|
1997-11-12 |
2004-10-14 |
Moskal Joseph R |
Detection and treatment of glyco-enzyme-related disease
|
|
US6899870B1
(en)
*
|
1998-03-11 |
2005-05-31 |
Board Of Regents, The University Of Texas System |
Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
|
|
DE69927013T2
(de)
*
|
1998-04-22 |
2006-06-29 |
Genvec, Inc. |
Effiziente reinigung von adenovirus
|
|
US6416992B1
(en)
*
|
1998-10-13 |
2002-07-09 |
Avigen, Inc. |
Compositions and methods for producing recombinant adeno-associated virus
|
|
US7691370B2
(en)
*
|
1998-10-15 |
2010-04-06 |
Canji, Inc. |
Selectivity replicating viral vector
|
|
EP1133316B1
(en)
*
|
1998-11-16 |
2009-01-21 |
Introgen Therapeutics, Inc. |
Formulation of adenovirus for gene therapy
|
|
US6689600B1
(en)
|
1998-11-16 |
2004-02-10 |
Introgen Therapeutics, Inc. |
Formulation of adenovirus for gene therapy
|
|
US7148035B1
(en)
*
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
US6210922B1
(en)
*
|
1998-11-30 |
2001-04-03 |
National Research Council Of Canada |
Serum free production of recombinant proteins and adenoviral vectors
|
|
FR2788064B1
(fr)
*
|
1998-12-31 |
2003-01-31 |
Aventis Pharma Sa |
Methode de separation de particules virales
|
|
AU779267B2
(en)
|
1998-12-31 |
2005-01-13 |
Centelion S.A.S. |
Method for separating viral particles
|
|
CA2364934C
(fr)
|
1999-02-22 |
2011-10-18 |
Transgene S.A. |
Procede d'obtention d'une preparation virale purifiee
|
|
US6795585B1
(en)
|
1999-07-16 |
2004-09-21 |
Eastman Kodak Company |
Representing digital images in a plurality of image processing states
|
|
JP2003518380A
(ja)
*
|
1999-12-29 |
2003-06-10 |
ジェンザイム・コーポレイション |
核酸および他の細胞性汚染混入物質からウイルスベクターを分離するための濾過助剤の使用方法
|
|
US6168941B1
(en)
*
|
2000-04-07 |
2001-01-02 |
Genvec, Inc. |
Method of producing adenoviral vector stocks
|
|
AU2001257420A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Zengen, Inc. |
A gene therapy system and method using alpha-MSH and its derivatives
|
|
US6783939B2
(en)
*
|
2000-07-07 |
2004-08-31 |
Alphavax, Inc. |
Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
|
|
TWI289158B
(en)
*
|
2000-08-10 |
2007-11-01 |
Oncolytics Biotech Inc |
Method of producing infectious reovirus
|
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
|
US20020064860A1
(en)
*
|
2000-11-29 |
2002-05-30 |
Schering Corporation |
Method for purifying adenoviruses
|
|
IL157304A0
(en)
*
|
2001-03-16 |
2004-02-19 |
Oncolytics Biotech Inc |
Method of extracting virus from cell culture
|
|
US20040146590A1
(en)
|
2001-03-22 |
2004-07-29 |
Iadarola Michael J |
Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
|
|
ATE431396T1
(de)
*
|
2001-03-27 |
2009-05-15 |
Vertex Pharma |
Für hcv-infektion geeignete zusammensetzungen und verfahren
|
|
EP1427835B1
(en)
|
2001-08-08 |
2016-01-20 |
The Trustees of the University of Pennsylvania |
Method for purification of viral vectors having proteins which bind sialic acid
|
|
US20040253210A1
(en)
*
|
2001-08-30 |
2004-12-16 |
Marjorie Robert-Guroff |
Adenovirus type7 vectors
|
|
WO2003023026A1
(en)
*
|
2001-09-06 |
2003-03-20 |
Alphavax, Inc. |
Alphavirus replicon vector systems
|
|
WO2003039459A2
(en)
*
|
2001-11-05 |
2003-05-15 |
Genvec, Inc. |
Viral vector production methods and compositions
|
|
US7056723B2
(en)
*
|
2001-12-20 |
2006-06-06 |
Bavarian Nordic A/S |
Method for the recovery and purification of poxviruses from infected cells
|
|
KR100451308B1
(ko)
*
|
2001-12-28 |
2004-10-06 |
선바이오(주) |
단백질 의약품 정제 방법에서의 바이러스 제거 방법
|
|
WO2003068804A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Novavax, Inc. |
Novel insect cell line
|
|
ES2261921T3
(es)
*
|
2002-02-20 |
2006-11-16 |
MERCK & CO., INC. |
Procedimiento para determinar la concentracion de particulas de adenovirus.
|
|
US20030180936A1
(en)
*
|
2002-03-15 |
2003-09-25 |
Memarzadeh Bahram Eric |
Method for the purification, production and formulation of oncolytic adenoviruses
|
|
US20030175688A1
(en)
*
|
2002-03-15 |
2003-09-18 |
Rukmini Pennathur-Das |
Method for the purification and production of oncolytic adenoviruses
|
|
US20030186832A1
(en)
*
|
2002-03-15 |
2003-10-02 |
Unilever Home & Personal Care Usa, Division Of Conopco, Inc. |
Isotropic liquid detergents with improved anti-redeposition
|
|
JP2005521417A
(ja)
*
|
2002-03-29 |
2005-07-21 |
メルク エンド カムパニー インコーポレーテッド |
アデノウイルスの大規模産生方法及びアデノウイルス種子ストック
|
|
DE60327069D1
(de)
*
|
2002-04-30 |
2009-05-20 |
Oncolytics Biotech Inc |
Verbesserte reinigungsmethode für viren
|
|
EP1506287B1
(en)
*
|
2002-05-14 |
2007-04-25 |
Merck & Co., Inc. |
Methods of adenovirus purification
|
|
US20030224354A1
(en)
*
|
2002-05-30 |
2003-12-04 |
Introgen Therapeutics Inc. |
Quantifying viral particles with intrinsic fluorescence
|
|
EP1371723A1
(en)
*
|
2002-06-12 |
2003-12-17 |
Procorde GmbH |
Process for preparing an adenovirus-containing preparation
|
|
US20040219516A1
(en)
*
|
2002-07-18 |
2004-11-04 |
Invitrogen Corporation |
Viral vectors containing recombination sites
|
|
US20040106184A1
(en)
*
|
2002-08-28 |
2004-06-03 |
Introgen Therapeutics Inc. |
Chromatographic methods for adenovirus purification
|
|
MXPA05003477A
(es)
*
|
2002-10-03 |
2005-07-22 |
Targegen Inc |
Agentes vasculo-estaticos y metodos de uso de los mismos.
|
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
EP1558748A4
(en)
*
|
2002-11-01 |
2008-10-22 |
Promega Corp |
CELL SYSE COMPOSITIONS, USE METHOD, DEVICE AND KIT
|
|
AU2003297039B2
(en)
*
|
2002-12-13 |
2009-03-05 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
|
AU2003297041B2
(en)
*
|
2002-12-13 |
2009-02-26 |
Alphavax, Inc. |
Alphavirus particles and methods for preparation
|
|
WO2004060346A2
(en)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
CA2802143C
(en)
|
2003-01-14 |
2018-06-19 |
Dana-Farber Cancer Institute |
Sparc encoding polynucleotide as a cancer therapy sensitizer
|
|
EP1608762B1
(en)
*
|
2003-03-20 |
2014-01-08 |
Alphavax, Inc. |
Improved alphavirus replicons and helper constructs
|
|
DE602004008451T2
(de)
*
|
2003-05-01 |
2008-05-15 |
Dsm Ip Assets B.V. |
Verfahren zur herstellung von biologischen substanzen durch perfusionskultivierung von suspendierten tierischen zellen
|
|
US20040229335A1
(en)
*
|
2003-05-15 |
2004-11-18 |
Introgen Therapeutics, Inc. |
Methods and compositions for the production of adenoviral vectors
|
|
CA2529053A1
(en)
*
|
2003-06-18 |
2004-12-29 |
Onyx Pharmaceuticals, Inc. |
Method for purifying virus
|
|
PT1651666E
(pt)
*
|
2003-07-11 |
2009-08-28 |
Alphavax Inc |
Vacinas de citomegalovírus à base de alfavírus
|
|
ES2356154T3
(es)
|
2003-07-21 |
2011-04-05 |
Transgene S.A. |
Citoquinas multifuncionales.
|
|
DE602004027538D1
(de)
*
|
2003-12-01 |
2010-07-15 |
Life Technologies Corp |
Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
|
|
CA2551026A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Schering Corporation |
Methods for producing a549 cell lines stable in serum-free medium suspension culture
|
|
CN1922308A
(zh)
*
|
2004-02-23 |
2007-02-28 |
克鲁塞尔荷兰公司 |
病毒纯化方法
|
|
CN100333797C
(zh)
*
|
2005-01-26 |
2007-08-29 |
彭朝晖 |
重组腺病毒p53制品在肿瘤治疗中的新用途
|
|
AU2005231507B2
(en)
|
2004-04-08 |
2012-03-01 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
PT1751289E
(pt)
|
2004-05-18 |
2009-03-31 |
Alphavax Inc |
Vectores de alfavirais derivados da tc-83, partículas e métodos
|
|
ES2932278T3
(es)
*
|
2004-06-01 |
2023-01-17 |
Genzyme Corp |
Composiciones y métodos para prevenir la agregación del vector AAV
|
|
US20050287616A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Gross Adam F |
Method of assaying denaturation of proteins
|
|
NZ588896A
(en)
|
2004-08-25 |
2012-05-25 |
Targegen Inc |
Heterocyclic compounds and methods of use
|
|
DE202004014949U1
(de)
*
|
2004-09-25 |
2004-11-18 |
Techno-Grafica Gmbh |
Vorrichtung zum Wärmebehandeln einer Beschichtung von Flachoffset-Druckplatten
|
|
DE102004049290A1
(de)
*
|
2004-10-09 |
2006-04-20 |
Bayer Healthcare Ag |
Verfahren zur Herstellung von Virusmaterial
|
|
US7901921B2
(en)
*
|
2004-10-22 |
2011-03-08 |
Oncolytics Biotech Inc. |
Viral purification methods
|
|
CN101080488A
(zh)
*
|
2004-11-03 |
2007-11-28 |
因特罗根治疗公司 |
生产和纯化腺病毒载体的新方法
|
|
CN100497640C
(zh)
*
|
2004-11-26 |
2009-06-10 |
中国人民解放军军事医学科学院生物工程研究所 |
一种高效生产重组腺病毒载体的方法
|
|
US20060166364A1
(en)
*
|
2004-12-22 |
2006-07-27 |
Introgen, Inc. |
Use of flexible bag containers for viral production
|
|
ES2526170T3
(es)
*
|
2004-12-23 |
2015-01-07 |
Medimmune, Llc |
Línea celular MDCK no tumorigénica para propagar virus
|
|
US20060205080A1
(en)
*
|
2005-03-01 |
2006-09-14 |
David Frey |
Formulations for therapeutic viruses having enhanced storage stability
|
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
|
ATE412737T1
(de)
*
|
2005-04-11 |
2008-11-15 |
Crucell Holland Bv |
Virusreinigung mit ultrafiltration
|
|
MX2007013725A
(es)
*
|
2005-05-05 |
2008-04-09 |
Sensient Flavors Inc |
Produccion de beta-glucanos y mananos.
|
|
WO2006133411A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
|
US20090216452A1
(en)
*
|
2005-07-05 |
2009-08-27 |
Develop Tech Resources |
Energy recovery within a fluid distribution network using geographic information
|
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
|
WO2007053452A1
(en)
|
2005-11-01 |
2007-05-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
DE602007009954D1
(de)
*
|
2006-03-22 |
2010-12-02 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid-targets
|
|
WO2007127366A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
|
AU2007347716B2
(en)
*
|
2006-09-15 |
2013-06-20 |
Medimmune, Llc |
MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
|
|
CL2008000249A1
(es)
|
2007-01-30 |
2008-05-30 |
Transgene Sa |
Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
|
|
US20080299624A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Edward Heslop |
Continuous fermentation apparatus and method
|
|
DK2947149T3
(en)
*
|
2007-06-21 |
2018-06-06 |
Alphavax Inc |
ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
|
|
JP2010539993A
(ja)
*
|
2007-10-08 |
2010-12-24 |
イントレキソン コーポレーション |
遺伝子操作した樹状細胞および癌の治療のための使用
|
|
CA2703263C
(en)
|
2007-11-01 |
2014-03-18 |
Perseid Therapeutics Llc |
Immunosuppressive polypeptides and nucleic acids
|
|
US20090253184A1
(en)
*
|
2008-01-23 |
2009-10-08 |
Introgen Therapeutics, Inc. |
Compositions and methods related to an adenoviral trans-complementing cell line
|
|
US10316352B2
(en)
*
|
2008-05-13 |
2019-06-11 |
Gen-Probe Incorporated |
Methods of capturing a target nucleic acid for amplification and detection using an inactivatable target capture oligomer
|
|
WO2009153563A1
(en)
*
|
2008-06-18 |
2009-12-23 |
Oxford Biomedica (Uk) Limited |
Virus purification
|
|
KR20110074563A
(ko)
|
2008-09-24 |
2011-06-30 |
메디뮨 엘엘씨 |
바이러스의 정제 방법
|
|
CN102216450B
(zh)
*
|
2008-09-24 |
2014-05-14 |
米迪缪尼有限公司 |
培养细胞、增殖和纯化病毒的方法
|
|
WO2010062757A1
(en)
*
|
2008-11-03 |
2010-06-03 |
Ligocyte Pharmaceuticals, Inc. |
Improved methods for isolating enveloped virus-based vlps free of infectious agents
|
|
EA019928B1
(ru)
|
2008-11-03 |
2014-07-30 |
Круселл Холланд Б.В. |
Способ получения аденовирусных векторов
|
|
EP2435666A2
(en)
*
|
2009-05-26 |
2012-04-04 |
Leviathan Energy Hydroelectric Ltd. |
Hydroelectric in-pipe turbine uses
|
|
CN103331185A
(zh)
*
|
2009-07-07 |
2013-10-02 |
索尼公司 |
微流体装置
|
|
CA2770075C
(en)
|
2009-08-07 |
2021-08-24 |
Perrine Martin |
Composition for treating hbv infection
|
|
WO2011045381A1
(en)
|
2009-10-15 |
2011-04-21 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
|
MX2012004222A
(es)
|
2009-10-15 |
2012-06-08 |
Crucell Holland Bv |
Metodo para purificacion de particulas de adenovirus.
|
|
MX342641B
(es)
|
2010-01-05 |
2016-10-07 |
Vascular Biogenics Ltd |
Metodos para uso de un agente adenoviral anti-angiogenico especifico.
|
|
MX338931B
(es)
|
2010-01-05 |
2016-05-06 |
Vascular Biogenics Ltd |
Composiciones y metodo para tratar gliobastoma (gbm).
|
|
US20130052165A1
(en)
*
|
2010-01-12 |
2013-02-28 |
Livnat Bangio |
Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby
|
|
PL2536829T3
(pl)
|
2010-02-15 |
2016-09-30 |
|
Sposób wytwarzania wektorów adenowirusowych Ad26
|
|
SG184833A1
(en)
*
|
2010-04-14 |
2012-11-29 |
Emd Millipore Corp |
Methods of producing high titer, high purity virus stocks and methods of use thereof
|
|
EP2603234B1
(en)
|
2010-08-12 |
2017-06-28 |
Yisheng Biopharma Holdings Ltd. |
Method for reducing dna impurities in viral compositions
|
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
|
US8892184B2
(en)
|
2010-10-18 |
2014-11-18 |
Siemens Medical Solutions Usa, Inc. |
Systems and methods for reducing interference in a dual modality imaging system
|
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
EP2461162A1
(en)
|
2010-12-03 |
2012-06-06 |
Texcell, . |
Method for determining the titre of viruses by using infectious standards
|
|
CN103476928B
(zh)
|
2010-12-09 |
2017-03-29 |
巴斯德研究所 |
用于获得高产量重组蛋白表达的基于mgmt的方法
|
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
TW201318637A
(zh)
|
2011-09-29 |
2013-05-16 |
Transgene Sa |
免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
|
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
KR102044051B1
(ko)
|
2012-03-12 |
2019-11-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
터미널 말단이 변경된 재조합 아데노바이러스의 배치
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
JP5845376B2
(ja)
|
2012-03-22 |
2016-01-20 |
クルセル ホランド ベー ヴェー |
Ｒｓｖに対するワクチン
|
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
JP6334525B2
(ja)
*
|
2012-07-26 |
2018-05-30 |
ブクタリ |
真核細胞に対するウイルスベクター組成物の作用を検出又は測定する方法並びにそれに使用されるバイオマーカー
|
|
JP6430949B2
(ja)
|
2012-10-23 |
2018-11-28 |
エモリー ユニバーシティ |
Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
|
|
PT2988780T
(pt)
|
2013-04-25 |
2019-03-25 |
Janssen Vaccines & Prevention Bv |
Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
|
|
KR20160003078A
(ko)
|
2013-05-03 |
2016-01-08 |
허니웰 인터내셔날 인코포레이티드 |
무연 솔더 접속을 위한 리드 프레임 구조체
|
|
CN105408348B
(zh)
|
2013-06-17 |
2021-07-06 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
|
KR102069561B1
(ko)
*
|
2013-07-11 |
2020-01-23 |
다카라 바이오 가부시키가이샤 |
외피 비보유 바이러스의 제조 방법
|
|
US9956166B2
(en)
|
2013-09-18 |
2018-05-01 |
Sorrento Therapeutics, Inc. |
Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
|
|
EP3063290B1
(en)
*
|
2013-10-30 |
2018-11-21 |
Merck Patent GmbH |
Method for isolating microorganisms from a complex sample
|
|
JP2017509489A
(ja)
|
2014-02-20 |
2017-04-06 |
ハネウェル・インターナショナル・インコーポレーテッド |
鉛フリーはんだ組成物
|
|
US11008547B2
(en)
|
2014-03-25 |
2021-05-18 |
Terumo Bct, Inc. |
Passive replacement of media
|
|
EP4729528A3
(en)
|
2014-04-25 |
2026-06-24 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
CN105316296A
(zh)
*
|
2014-06-13 |
2016-02-10 |
亚宝药业太原制药有限公司 |
一种纯化腺病毒颗粒的方法
|
|
WO2016040441A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
GB201417042D0
(en)
|
2014-09-29 |
2014-11-12 |
Fkd Therapies Oy |
Method
|
|
EP3215191B1
(en)
|
2014-11-05 |
2024-08-14 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
SG11201704919SA
(en)
*
|
2015-01-13 |
2017-07-28 |
Alfa Wassermann Inc |
Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
CA2975432A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
WO2017004592A1
(en)
|
2015-07-02 |
2017-01-05 |
Terumo Bct, Inc. |
Cell growth with mechanical stimuli
|
|
AU2016289496B2
(en)
|
2015-07-07 |
2021-02-04 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
CN107847580B
(zh)
|
2015-07-07 |
2022-08-12 |
扬森疫苗与预防公司 |
针对rsv的疫苗
|
|
US9663766B2
(en)
*
|
2015-07-24 |
2017-05-30 |
Bio-Rad Laboratories, Inc. |
Methods for purifying adenovirus vectors
|
|
IL258491B2
(en)
|
2015-10-16 |
2023-09-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a particular lineage
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
AU2017248018A1
(en)
|
2016-04-05 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
|
MX2018012094A
(es)
|
2016-04-05 |
2019-01-10 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
|
|
DK3722435T3
(da)
*
|
2016-04-14 |
2025-11-17 |
Ferring Ventures Ltd |
Fixed-bed-bioreaktor med pumpe/rør-system med konstant flow
|
|
RS67367B1
(sr)
*
|
2016-04-14 |
2025-11-28 |
Ferring Ventures Ltd |
Bioreaktor sa fiksiranim slojem sa pumpom/sistemom creva sa konstantnim protokom
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
IL297576B2
(en)
|
2016-05-18 |
2024-02-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
WO2017205667A1
(en)
|
2016-05-25 |
2017-11-30 |
Terumo Bct, Inc. |
Cell expansion
|
|
SG11201810078PA
(en)
|
2016-05-30 |
2018-12-28 |
Janssen Vaccines & Prevention Bv |
Stabilized pre-fusion rsv f proteins
|
|
US11104874B2
(en)
|
2016-06-07 |
2021-08-31 |
Terumo Bct, Inc. |
Coating a bioreactor
|
|
US11685883B2
(en)
|
2016-06-07 |
2023-06-27 |
Terumo Bct, Inc. |
Methods and systems for coating a cell growth surface
|
|
US11001858B2
(en)
|
2016-06-20 |
2021-05-11 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
US10053660B2
(en)
|
2016-07-12 |
2018-08-21 |
California Institute Of Technology |
Substrates for high-density cell growth and metabolite exchange
|
|
US10744196B2
(en)
|
2016-07-14 |
2020-08-18 |
Janssen Vaccines & Prevention B.V. |
HPV vaccines
|
|
EP3831281B1
(en)
|
2016-08-30 |
2026-02-25 |
The Regents of The University of California |
Devices and systems for biomedical targeting and delivery
|
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
WO2018080573A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
|
CN108085301B
(zh)
*
|
2016-11-22 |
2021-10-26 |
贺道耀 |
从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
|
|
US10294452B2
(en)
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
|
WO2018106888A1
(en)
*
|
2016-12-08 |
2018-06-14 |
Temple University-Of The Commonwealth System Of Higher Education |
Small animal models for in vivo testing of polyomavirus therapeutics
|
|
WO2018148246A1
(en)
|
2017-02-07 |
2018-08-16 |
Massachusetts Institute Of Technology |
Methods and compositions for rna-guided genetic circuits
|
|
JP7393945B2
(ja)
|
2017-03-31 |
2023-12-07 |
テルモ ビーシーティー、インコーポレーテッド |
細胞増殖
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
CN107384873A
(zh)
*
|
2017-09-05 |
2017-11-24 |
成都汇宇生物技术有限公司 |
重组腺病毒的纯化方法
|
|
AU2018333566A1
(en)
|
2017-09-15 |
2020-02-27 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against RSV
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
WO2019086463A1
(en)
|
2017-10-30 |
2019-05-09 |
Baxalta GmbH |
Environmentally compatible detergents for inactivation of lipid-enveloped viruses
|
|
US11339377B2
(en)
*
|
2017-11-08 |
2022-05-24 |
Bluesky Immunotherapies Gmbh |
SO3 chromatography for use in a method for virus purification
|
|
EP3762500A1
(en)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
WO2020010110A1
(en)
|
2018-07-03 |
2020-01-09 |
Unum Therapeutics Inc. |
Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
WO2020037066A1
(en)
|
2018-08-14 |
2020-02-20 |
Unum Therapeutics Inc. |
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
|
|
CA3107770C
(en)
|
2018-08-16 |
2023-09-05 |
Emd Millipore Corporation |
Closed bioprocessing device
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
EP3833398A4
(en)
|
2018-09-21 |
2021-12-22 |
University of Connecticut |
COMPOSITIONS AND METHODS OF RESTORING PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN'S SYNDROME IN HUMANS
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
CN113166208B
(zh)
|
2018-10-02 |
2024-11-22 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
PE20211469A1
(es)
|
2018-11-13 |
2021-08-05 |
Janssen Vaccines And Prevention B V |
Proteinas f de prefusion del vrs estabilizadas
|
|
WO2020123524A1
(en)
*
|
2018-12-11 |
2020-06-18 |
Erbi Biosystems, Inc. |
Methods of manufacturing cell based products using small volume perfusion processes
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
US11542526B2
(en)
|
2019-02-21 |
2023-01-03 |
Unleash Immuno Oncolytics, Inc. |
Oncolytic adenoviral vector and methods of use
|
|
CN110093455B
(zh)
*
|
2019-04-27 |
2020-03-17 |
中国医学科学院病原生物学研究所 |
一种呼吸道病毒的检测方法
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
CN112175996A
(zh)
*
|
2019-07-05 |
2021-01-05 |
杭州荣泽生物科技有限公司 |
一种基因治疗载体的制备方法和用途
|
|
EP4010465A1
(en)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
CN114929875A
(zh)
|
2019-11-15 |
2022-08-19 |
希望之城 |
包含用于腺相关病毒的强化产生的高密度细胞呼吸器的用于产生生物产物的系统、装置和方法
|
|
CN110894494B
(zh)
*
|
2019-11-22 |
2022-09-27 |
广西梧州制药（集团）股份有限公司 |
一种大规模高密度悬浮培养293细胞高产腺病毒的方法
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
GB202005732D0
(en)
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
US12630842B2
(en)
|
2020-05-13 |
2026-05-19 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
CN112226418B
(zh)
*
|
2020-09-25 |
2022-07-08 |
阜外华中心血管病医院 |
重组腺相关病毒纯化方法
|
|
US20230374542A1
(en)
|
2020-10-07 |
2023-11-23 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
|
|
CN112293394B
(zh)
*
|
2020-10-30 |
2022-11-25 |
海南德安欣有害生物防治科技有限公司 |
一种捕鼠装置及捕鼠方法
|
|
KR20230078805A
(ko)
|
2020-11-02 |
2023-06-02 |
바이오마린 파머수티컬 인크. |
아데노-연관 바이러스의 농축 공정
|
|
GB202019454D0
(en)
*
|
2020-12-10 |
2021-01-27 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Method for purifying virus
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
JP2024515626A
(ja)
|
2021-04-16 |
2024-04-10 |
アスクレピオス バイオファーマシューティカル， インコーポレイテッド |
血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
|
|
US12680110B2
(en)
|
2021-08-12 |
2026-07-14 |
The University Of Chicago |
One-step method for producing adenoviral vectors
|
|
JP2024534894A
(ja)
|
2021-09-03 |
2024-09-26 |
ビオマリン プハルマセウトイカル インコーポレイテッド |
Ａａｖカプシド組成物及び送達方法
|
|
EP4396201A1
(en)
|
2021-09-03 |
2024-07-10 |
BioMarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
WO2023034990A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
WO2023034989A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
US20240384242A1
(en)
|
2021-09-03 |
2024-11-21 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
WO2023034980A1
(en)
|
2021-09-03 |
2023-03-09 |
Bomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
MX2024004009A
(es)
|
2021-09-27 |
2024-06-19 |
Sotio Biotech Inc |
Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos.
|
|
EP4426716A1
(en)
|
2021-11-02 |
2024-09-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
CA3237201A1
(en)
|
2021-11-16 |
2023-05-25 |
Sotio Biotech Inc. |
Treatment of myxoid/round cell liposarcoma patients
|
|
EP4433169A1
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
CA3240342A1
(en)
|
2021-12-16 |
2023-06-22 |
Gopal SAPKOTA |
Targeted degradation of alpha-synuclein
|
|
US20250346920A1
(en)
|
2022-01-25 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
JP2025507338A
(ja)
|
2022-02-08 |
2025-03-18 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖカプシドバリアント及びその使用
|
|
GB202201713D0
(en)
|
2022-02-10 |
2022-03-30 |
Univ Dundee |
An affinity directed phosphatase system for targeted protein dephosphorylation
|
|
CN115354033A
(zh)
*
|
2022-03-25 |
2022-11-18 |
上海碧博生物医药科技有限公司 |
一种细胞裂解液、细胞裂解方法及该方法在收获aav的应用
|
|
EP4532515A1
(en)
|
2022-06-02 |
2025-04-09 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024006741A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
|
US20260053924A1
(en)
|
2022-08-19 |
2026-02-26 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
JP2025535203A
(ja)
|
2022-09-15 |
2025-10-23 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
UY40443A
(es)
|
2022-09-22 |
2024-02-15 |
Biomarin Pharm Inc |
Tratamiento de la miocardiopatía con vectores de genoterapia con aav
|
|
UY40442A
(es)
|
2022-09-22 |
2024-02-15 |
Biomarin Pharm Inc |
Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
|
|
WO2024215987A1
(en)
|
2023-04-14 |
2024-10-17 |
Sotio Biotech Inc. |
IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
|
|
EP4694916A1
(en)
|
2023-04-14 |
2026-02-18 |
SOTIO Biotech Inc. |
Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
JP2026515815A
(ja)
|
2023-05-03 |
2026-05-19 |
ボイジャー セラピューティクス インコーポレイテッド |
Ｃｄｋｌ５欠損に関連する障害の治療のための組成物及び方法
|
|
WO2024229173A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
IL324036A
(en)
|
2023-05-03 |
2025-12-01 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2024229164A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
JP2026515970A
(ja)
|
2023-05-04 |
2026-05-19 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖカプシドバリアント及びその使用
|
|
CN116731981A
(zh)
*
|
2023-06-20 |
2023-09-12 |
天津瑞普生物技术股份有限公司 |
一种鸡新城疫病毒大规模悬浮培养方法
|
|
WO2025030010A1
(en)
|
2023-08-01 |
2025-02-06 |
Vor Biopharma Inc. |
Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
|
|
WO2025038802A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025038805A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025038796A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025038430A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025038795A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025038800A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
AR134555A1
(es)
|
2023-12-05 |
2026-01-28 |
Voyager Therapeutics Inc |
Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina
|
|
WO2025122530A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
CN117551624A
(zh)
*
|
2024-01-11 |
2024-02-13 |
深圳源兴基因技术有限公司 |
一种基于无血清悬浮扩增的高效回收腺病毒的方法
|
|
WO2025214477A1
(en)
|
2024-04-12 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Treatment of genetic cardiomyopathies with aav gene therapy vectors
|
|
WO2026028089A1
(en)
|
2024-07-29 |
2026-02-05 |
Novartis Ag |
Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|
|
WO2026096600A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
|
|
WO2026096611A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
|
|
WO2026096603A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering syntaxin-binding protein-1
|
|
WO2026096599A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering syntaxin-binding protein-1
|
|
WO2026102000A1
(en)
|
2024-11-06 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
NL2039429B1
(en)
|
2024-12-20 |
2026-07-13 |
Academisch Ziekenhuis Leiden |
Pabpn1 isoforms for use in therapy
|